You have 9 free searches left this month | to do more

ifosfamide

Ifosfamide is a drug used to treat Sarcoma, Lymphoma, Leukemia, and other conditions. Ifosfamide is being actively studied in 73 studies and prior, has been studied in 144.

Top SponsorsTop SitesTop Investigators
Children's Oncology GroupMemorial Sloan-Kettering Cancer CenterMartin Schrappe
Memorial Sloan Kettering Cancer CenterRoswell Park Cancer InstituteAjay Gopal
M.D. Anderson Cancer CenterChildren's National Medical CenterChristopher Ryan
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
O
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Recruiting
  • Soft Tissue Sarcoma
  • Bergen, Norway
  • +1 more
2021-09-10
Sep 10, 2021
J
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
Terminated
Has Results
  • Sarcoma
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center at UCLA
2020-07-29
Jul 29, 2020
I
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Recruiting
  • Non-metastatic Soft-tissue Sarcoma
  • Resectable
  • Bordeaux, France
  • +9 more
2022-02-01
Feb 1, 2022
S
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
Recruiting
  • Penile Cancer
  • Albumin-Bound Paclitaxel
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2020-08-18
Aug 18, 2020
E
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma - 2021
Terminated
  • Sarcoma, Soft Tissue
  • Brussels, Belgium
  • +12 more
2021-09-10
Sep 10, 2021
U
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Active, not recruiting
Has Results
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-12-29
Dec 29, 2021
E
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma - 2019
Completed
Has Results
  • Soft Tissue Sarcoma
  • Miami, Florida
  • +5 more
2020-08-22
Aug 22, 2020
M
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Active, not recruiting
  • Germ Cell Tumors
  • Los Angeles, California
  • +12 more
2021-07-01
Jul 1, 2021
M
A Study of N9 Chemotherapy in Children With Neuroblastoma
Recruiting
  • Neuroblastoma
  • Pediatric Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-08-11
Aug 11, 2021
I
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma - 2018
Completed
  • Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
  • Santa Monica, California
    Sarcoma Oncology Center
2022-01-27
Jan 27, 2022
P
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Withdrawn
  • Effect of Drugs
  • +2 more
  • Beijing, Beijing, China
    Lu Xie
2020-05-15
May 15, 2020
U
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
2022-02-02
Feb 2, 2022
T
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • Brugge, Belgium
  • +21 more
2021-05-05
May 5, 2021
M
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Active, not recruiting
  • Sarcoma
  • pegfilgrastim
  • +5 more
  • Baltimore, Maryland
  • +1 more
2022-03-25
Mar 25, 2022
S
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Seattle, Washington
    Swedish Cancer Institute
2021-03-01
Mar 1, 2021
I
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis - 2020
Completed
  • Germ Cell Tumors
  • Angers, France
  • +11 more
2021-01-11
Jan 11, 2021
R
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Active, not recruiting
Has Results
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2021-10-11
Oct 11, 2021
C
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
Active, not recruiting
  • Pleuropulmonary Blastoma
  • Minneapolis, Minnesota
    Anne K Harris
2021-05-26
May 26, 2021
F
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Recruiting
  • Sarcoma, Soft Tissue
  • Shanghai, Shanghai, China
    Fudan University, Cancer Hospital
2020-07-13
Jul 13, 2020
E
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Active, not recruiting
Has Results
  • Tumors
  • +3 more
  • Houston, Texas
  • +18 more
2021-09-02
Sep 2, 2021
I
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Retroperitoneal Sarcomas (TORNADO)
Not yet recruiting
  • Retroperitoneal Sarcoma
  • Resectable Sarcoma
  • Bordeaux, France
  • +3 more
2022-03-04
Mar 4, 2022
N
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Recruiting
  • Non-Hodgkin Lymphoma
  • +5 more
  • Valhalla, New York
    New York Medical College
2021-09-01
Sep 1, 2021
U
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
2021-10-25
Oct 25, 2021
N
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Recruiting
  • NK-Cell Lymphoma
  • +2 more
  • San Francisco, California
  • +1 more
2021-09-01
Sep 1, 2021
M
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Active, not recruiting
  • Testicular Cancer
  • Houston, Texas
  • +1 more
2021-01-06
Jan 6, 2021